Home > Resources > Whitepapers > Applying Model Reduction to Lessen the Complexity of Quantitative Systems Pharmacology Models

Applying Model Reduction to Lessen the Complexity of Quantitative Systems Pharmacology Models

One of the greatest challenges in drug development is the high attrition rate obtained in Phase 2 clinical trials, resulting in significantly elevated R&D costs and time. In fact, approximately 80% of new drugs that move into Phase 2—the phase when a new drug is first tested in humans—fail to demonstrate safety and efficacy.

Spotlight

Jubilant Life Sciences Ltd

Jubilant Life Sciences Limited, is an integrated global pharmaceutical and life sciences company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients. It also provides services in Contract Manufacturing of Sterile Injectables and Drug Discovery . The Company’s strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain.

OTHER WHITEPAPERS

The Next Generation of Rare Disease Drug Policy

whitePaper | April 7, 2022

The United States defines a rare disease as a condition affecting fewer than 200,000 people in the country or one in which “there is no reasonable expectation” of recovering research and development costs.1 Examples of rare diseases include genetically-linked cancers, cystic fibrosis, and debilitating pediatric conditions like Gaucher disease and spinal muscular atrophy

Pharma R&D Annual Review 2023

whitePaper | April 20, 2023

Welcome to Pharmaprojects’ 2023 review of trends in pharmaceutical R&D. For over 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article, I’llexamine the state of play at the start of 2023.

Pharma R And D Review

whitePaper | February 11, 2021

Welcome to Pharmaprojects’ 2021 review of trends in pharmaceutical R&D. For almost 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article I’ll examine the state of play at the start of 2021.

Assessing drug target association from biological evidences

whitePaper | July 7, 2022

The full drug target profile identification is many times a necessary step in drug development process. Recently, the move to a more holistic approach in drug discovery has resulted in the increasing use of cell-based assays to discover new biologically active small molecules.

More Whitepapers

Applying Model Reduction to Lessen the Complexity of Quantitative Systems Pharmacology Models